

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|---|--|---|
| ACNE AGENTS, TOPICAL | ANTI-INFECTIVE | | <p>A trial of at least 30 days each with at least one preferred retinoid and two unique chemical entities in at least two other subclasses, including the generic version of a requested non-preferred product, will be required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. (In cases of pregnancy, a trial of retinoids will not be required.)</p> <p>PA required after 17 years of age for tretinoin products.</p> <p>With the exception of Duac CS, acne kits are non-preferred</p> |
| | AKNE-MYCIN (erythromycin) AZELEX (azelaic acid) clindamycin erythromycin sodium sulfacetamide | CLEOCIN-T (clindamycin) EVOCLIN (clindamycin) KLARON (sodium sulfacetamide) | |
| | RETINOIDS | | |
| | RETIN A liquid & Micro (tretinoin) TAZORAC (tazarotene) tretinoin cream, gel | AVITA DIFFERIN (adapalene) RETIN-A cream, gel (tretinoin) | |
| | KERATOLYTICS (Benzoyl Peroxides) | | |
| | benzoyl peroxide ETHEXDERM (benzoyl peroxide) OSCION (benzoyl peroxide) | BENZAC WASH (benzoyl peroxide) BREVOXYL (benzoyl peroxide) DESQUAM (benzoyl peroxide) LAVOCLEN (benzoyl peroxide) TRIAZ (benzoyl peroxide) | |
| COMBINATION AGENTS | | | |
| benzoyl peroxide/urea DUAC CS (benzoyl peroxide/ clindamycin) erythromycin/benzoyl peroxide sulfacetamide sodium/sulfur wash/cleanser | BENZACLIN GEL (benzoyl peroxide/clindamycin) BENZAMYCIN PAK (benzoyl peroxide/erythromycin) CLENIA (sulfacetamide sodium/sulfur) INOVA 4/1 (benzoyl peroxide/salicylic acid) NUOX (benzoyl peroxide/sulfur) PLEXION (sulfacetamide sodium/sulfur) PRASCION (sulfacetamide sodium/sulfur) ROSAC (sulfacetamide sodium/avobenzone/sulfur) ROSADERM (sulfacetamide sodium/sulfur) ROSANIL (sulfacetamide sodium/sulfur) ROSULA (sulfacetamide sodium/sulfur/urea) sulfacetamide sodium/sulfur lotion, gel SULFOXYL (benzoyl peroxide/sulfur) SULFATOL (sulfacetamide sodium/sulfur/urea) ZIANA (clindamycin/tretinoin) | | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|-----------------------------------|--|--|---|
| ALZHEIMER'S AGENTS | CHOLINESTERASE INHIBITORS | | A trial of a preferred agent will be required before a non-preferred agent in this class will be authorized |
| | ARICEPT (donepezil) ARICEPT ODT(donepezil) EXELON (rivastigmine) | COGNEX (tacrine) galantamine RAZADYNE (galantamine) RAZADYNE ER (galantamine) | |
| | NMDA RECEPTOR ANTAGONIST | | |
| | NAMENDA (memantine) | | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|--|---|--|
| ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral) | APAP/codeine ASA/codeine codeine dihydrocodeine/ APAP/caffeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone levorphanol morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone propoxyphene/APAP ROXICET (oxycodone/acetaminophen) tramadol tramadol/APAP VOPAC (codeine/acetaminophen) | ACTIQ (fentanyl) butalbital/APAP/caffeine/codeine butalbital/ASA/caffeine/codeine butorphanol COMBUNOX (oxycodone/ibuprofen) DARVO CET (propoxyphene/APAP) DARVON (propoxyphene) DEMEROL (meperidine) DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP) LYNOX (oxycodone/APAP) meperidine OPANA (oxymorphone) oxycodone/ibuprofen OXYFAST (oxycodone) OXYIR (oxycodone) PANLOR (dihydrocodeine/ APAP/caffeine) PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) propoxyphene ROXANOL (morphine) TALACEN (pentazocine/APAP) TALWIN NX (pentazocine/naloxone) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen) XODOL (hydrocone/acetaminophen) ZAMICET (hydrocodone/APAP) ZYDONE (hydrocodone/acetaminophen) | <p>A trial of at least four (4) chemically distinct (based on narcotic ingredient only) preferred agents, including the generic formulation of a requested non-preferred product, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present.</p> <p>Fentanyl lozenges will only be approved as an adjunct to a long-acting agent. Fentanyl lozenges will not be approved for monotherapy.</p> <p>Limits: Quantities exceeding 240 tablets per 30 days (8 tablets/day) for agents containing 500 mg of acetaminophen will require a prior authorization.</p> |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|--|---|---|
| ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral) | fentanyl KADIAN (morphine) methadone morphine ER | AVINZA (morphine) DURAGESIC (fentanyl) MS CONTIN (morphine) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) ULTRAM ER (tramadol) | A total of four (4) preferred narcotic analgesics, including at least one long-acting agent, must be tried for at least six (6) days before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. The generic form of the requested non-preferred agent, if available, must be tried before the non-preferred agent will be approved. Exception: Oxycodone ER will be authorized if a diagnosis of cancer is submitted without a trial of the preferred agents. |
| ANDROGENIC AGENTS | ANDRODERM (testosterone) ANDROGEL (testosterone) | TESTIM (testosterone) | The non-preferred agents will be approved only if one of the exceptions on the PA form is present. |
| ANGIOTENSIN MODULATORS | ACE INHIBITORS | | Each of the preferred agents in the corresponding group and the generic formulation of the requested non-preferred agent, with the exception of Direct Renin Inhibitors, must be tried for at least two weeks each before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present. |
| | ALTACE benazepril captopril enalapril fosinopril lisinopril quinapril | ACCUPRIL (quinapril) ACEON (perindopril) CAPOTEN (captopril) LOTENSIN (benazepril) MAVIK (trandolapril) moexipril MONOPRIL (fosinopril) PRINIVIL (lisinopril) ramipril trandolapril UNIVASC (moexipril) VASOTEC (enalapril) ZESTRIL (lisinopril) | |
| | ACE INHIBITOR COMBINATION DRUGS | | |
| | benazepril/amlodipine benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ | ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LEXXEL (enalapril/felodipine) LOTENSIN HCT (benazepril/HCTZ) LOTREL (benazepril/amlodipine) moexipril/HCTZ MONOPRIL HCT (fosinopril/HCTZ) PRINZIDE (lisinopril/HCTZ) TARKA (trandolapril/verapamil) UNIRETIC (moexipril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|--|--|--|
| ANGIOTENSIN MODULATORS | ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs) | | |
| | AVAPRO (irbesartan) BENICAR (olmesartan) COZAAR (losartan) DIOVAN (valsartan) MICARDIS (telmisartan) | ATACAND (candesartan) TEVETEN (eprosartan) | |
| | ARB COMBINATIONS | | |
| | AVALIDE (irbesartan/HCTZ) BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) EXFORGE (valsartan/amlodipine) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) | ATACAND-HCT (candesartan/HCTZ) AZOR (olmesartan/amlodipine) TEVETEN-HCT (eprosartan/HCTZ) | |
| | DIRECT RENIN INHIBITORS | | |
| | TEKTURNA (aliskiren) | A thirty-day trial of one of the preferred ACE, ARB, or combination agents, at the maximum tolerable dose, is required before Tekturna will be approved. | |
| ANTICOAGULANTS, INJECTABLE^{CL} | ARIXTRA (fondaparinux) FRAGMIN (dalteparin) LOVENOX (enoxaparin) | INNOHEP (tinzaparin) | A trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|---|---|---|
| ANTICONVULSANTS | ADJUVANTS | | Treatment naive patients must have a trial of a preferred agent before a non-preferred agent in its corresponding class will be authorized. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present. |
| | carbamazepine CARBATROL (carbamazepine) DEPAKOTE ER (divalproex) DEPAKOTE SPRINKLE (divalproex) divalproex EC FELBATOL (felbamate) gabapentin GABITRIL (tiagabine) KEPPRA (levetiracetam) LAMICTAL (lamotrigine) LYRICA (pregabalin) oxcarbazepine TOPAMAX (topiramate) TRILEPTAL (oxcarbazepine) valproic acid zonisamide | DEPAKENE (valproic acid) DEPAKOTE (divalproex) EQUETRO (carbamazepine) KEPPRA XR (levetiracetam) lamotrigine NEURONTIN (gabapentin) STAVZOR (valproic acid) ^{NR} TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) ZONEGRAN (zonisamide) | |
| | BARBITURATES | | |
| | mephobarbital phenobarbital primidone | MEBARAL (mephobarbital) MYSOLINE (primidone) | |
| | BENZODIAZEPINES | | |
| | clonazepam DIASTAT (diazepam rectal) diazepam | KLONOPIN (clonazepam) | |
| | HYDANTOINS | | |
| | DILANTIN INFATABS (phenytoin) PEGANONE (ethotoin) phenytoin | CEREBYX (fosphenytoin) DILANTIN (phenytoin) EPITOL (phenytoin) PHENYTEK (phenytoin) | |
| SUCCINIMIDES | | | |
| CELONTIN (methsuximide) ethosuximide | ZARONTIN (ethosuximide) | | |
| ANTIDEPRESSANTS, OTHER (second generation, non-SSRI) | bupropion SR CYMBALTA (duloxetine) EFFEXOR XR (venlafaxine) mirtazapine trazodone | bupropion IR bupropion XL DESYREL (trazodone) EFFEXOR (venlafaxine) EMSAM (selegiline) | A non-preferred agent will only be authorized if there has been a six-week trial of an SSRI and a preferred agent in this class unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|-------------------------------|---|--|---|
| | | nefazodone PRISTIQ (desvenlafaxine) REMERON (mirtazapine) venlafaxine venlafaxine ER WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion) | |
| ANTIDEPRESSANTS, SSRIs | citalopram fluoxetine fluvoxamine paroxetine sertraline | CELEXA (citalopram) LEXAPRO (escitalopram) LUVOX (fluvoxamine) LUVOX CR (fluvoxamine) PAXIL (paroxetine) PAXIL CR (paroxetine) paroxetine ER PEXEVA (paroxetine) PROZAC (fluoxetine) RAPIFLUX (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline) | A trial of two of the preferred agents will be required, for at least 30 days, before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Upon hospital discharge, patients admitted with a primary mental health diagnosis and have been stabilized on a non-preferred SSRI will receive authorization to continue that drug. |
| ANTIEMETICS | | 5HT3 RECEPTOR BLOCKERS | |
| | ondansetron ondansetron ODT | ANZEMET (dolasetron) KYTRIL (granisetron) granisetron SANCUSO (granisetron) ^{NR} | A trial of the preferred agent is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. PA is required when limits are exceeded. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|-----------------------------|---|---|--|
| | | ZOFTRAN (ondansetron) ZOFTRAN ODT (ondansetron) | |
| | CANNABINOIDS | | Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to conventional treatments such as promethazine or ondansetron and are over 18 years of age. Marinol will be authorized only for the treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol, the prophylaxis of chemotherapy induced nausea and vomiting unresponsive to ondansetron or promethazine and for patients between the ages of 18 and 65 years of age. |
| | | CESAMET (nabilone) MARINOL (dronabinol) | |
| | SUBSTANCE P ANTAGONISTS | | PA is required when limits are exceeded. |
| EMEND (aprepitant) | | | |
| ANTIFUNGALS, ORAL | clotrimazole fluconazole* ketoconazole ^{CL} nystatin terbinafine ^{CL} | ANCOBON (flucytosine) DIFLUCAN (fluconazole) GRIFULVIN V (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) SPORANOX (itraconazole) VFEND (voriconazole) | Non-preferred agents will be approved only if one of the exceptions on the PA form is present. *PA is required when limits are exceeded. PA is not required for Grifulvin-V Suspension for children up to 6 years of age for the treatment of tinea capitis. |
| ANTIFUNGALS, TOPICAL | ANTIFUNGALS | | Two of the preferred agents must be tried for at least two weeks each before one of the non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
| | econazole ketoconazole MENTAX (butenafine) NAFTIN (naftifine) | ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) LOPROX (ciclopirox) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|---|---|--|
| | nystatin | MYCOSTATIN (nystatin) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PENLAC (ciclopirox) SPECTAZOLE (econazole) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole) | |
| | ANTIFUNGAL/STEROIDCOMBINATIONS | | |
| | clotrimazole/betamethasone nystatin/triamcinolone | LOTRISONE (clotrimazole/betamethasone) MYCOLOG (nystatin/triamcinolone) | |
| ANTI-HISTAMINES, MINIMALLY SEDATING | ANTI-HISTAMINES | | A trial of at least 2 chemically distinct preferred agents, in the age appropriate form, including the generic formulation of a requested non-preferred product, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| | ALAVERT (loratadine) cetirizine (OTC) loratadine TAVIST-ND (loratadine) | ALLEGRA (fexofenadine) CLARINEX Tablets (desloratadine) CLARINEX REDITABS (desloratadine) CLARINEX Syrup (desloratadine) CLARITIN (loratadine) fexofenadine XYZAL (levocetirizine) ZYRTEC (Rx and OTC) (cetirizine) ZYRTEC SYRUP (Rx and OTC) (cetirizine) | |
| | ANTI-HISTAMINE/DECONGESTANT COMBINATIONS | | |
| | ALAVERT-D (loratadine/pseudoephedrine) cetirizine /pseudoephedrine (OTC) loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine) | ALLEGRA-D (fexofenadine/pseudoephedrine) CLARINEX-D (desloratadine/pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) ZYRTEC-D (Rx and OTC) (cetirizine/pseudoephedrine) | |
| ANTIMIGRAINE AGENTS, TRIPTANS | TRIPTANS | | All of the preferred agents must be tried before a Non-preferred agent will be approved unless one of the exceptions on the PA form is present. Quantity limits apply for this drug class. |
| | AMERGE (naratriptan) IMITREX (sumatriptan) MAXALT (rizatriptan) RELPAX (eletriptan) | AXERT (almotriptan) FROVA (frovatriptan) ZOMIG (zolmitriptan) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|---|--|--|
| | TRIPTAN COMBINATIONS | | |
| | TREXIMET (sumatriptan/naproxen sodium) | | |
| ANTIPARKINSON'S AGENTS (Oral) | ANTICHOLINERGICS | | Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents, in the corresponding class, before a non-preferred agent will be authorized. |
| | benztropine KEMADRIN (procyclidine) trihexyphenidyl | COGENTIN (benztropine) | |
| | COMT INHIBITORS | | |
| | | COMTAN (entacapone) TASMAR (tolcapone) | |
| | DOPAMINE AGONISTS | | |
| | ropinirole | MIRAPEX (pramipexole) REQUIP (ropinirole) REQUIP XL (ropinirole) | |
| | OTHER ANTIPARKINSON'S AGENTS | | |
| carbidopa/levodopa selegiline STALEVO (levodopa/carbidopa/entacapone) | AZILECT (rasagiline) ELDEPRYL (selegiline) levodopa/carbidopa ODT PARCOPA (levodopa/carbidopa) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline) | | |
| ANTIPSYCHOTICS, ATYPICAL (Oral) | ORAL | | Treatment naïve patients for this class of drugs will be required to try a preferred agent for two weeks unless one of the exceptions on the PA form is present. Upon discharge, hospitalized patients stabilized on non-preferred agents will receive |
| | clozapine GEODON (ziprasidone) INVEGA (paliperidone) RISPERDAL (risperidone) | ABILIFY (aripiprazole) CLOZARIL (clozapine) FAZACLO (clozapine) risperidone | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|-----------------------------|---|--|--|
| | SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) | ZYPREXA (olanzapine) | authorization to continue these drugs for labeled indications and at recommended dosages. |
| | ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS | | |
| | | SYMBYAX (olanzapine/fluoxetine) | Abilify will be prior authorized for MDD if the following criteria are met: <ol style="list-style-type: none"> 1. The patient is at least 18 year of age. 2. Diagnosis of Major Depressive Disorder (MDD) not responsive to other antidepressants. 3. Evidence of trials of appropriate therapeutic duration at a maximum tolerable dose of at least two (2) of the following agents: Selective Serotonin Reuptake Inhibitors (SSRI), Norepinephrine Reuptake Inhibitors, or bupropion. 4. Prescribed in conjunction with an SSRI, SNRI or bupropion. <p>The daily dose does not exceed 15 mg.</p> |
| ANTIVIRALS (Oral) | ANTI HERPES | | All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
| | acyclovir VALTREX (valacyclovir) | famciclovir FAMVIR (famciclovir) ZOVIRAX (acyclovir) | |
| | ANTI INFLUENZA | | |
| | amantadine | FLUMADINE (rimantadine) RELENZA (zanamivir) rimantadine SYMMETREL (amantadine) TAMIFLU (oseltamivir) | All of the appropriate preferred agents must be tried before the non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
| ATOPIC DERMATITIS | ELIDEL (pimecrolimus) PROTOPIC (tacrolimus) | | |
| BETA BLOCKERS (Oral) | BETA BLOCKERS | | A trial of three chemically distinct preferred agents, |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|--|---|---|
| | acebutolol atenolol betaxolol bisoprolol metoprolol metoprolol ER nadolol pindolol propranolol propranolol ER sotalol timolol | BETAPACE (sotalol) BLOCADREN (timolol) BYSTOLIC (nebivolol) CARTROL (carteolol) CORGARD (nadolol) INDERAL LA (propranolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol) | including the generic formulation of a requested non-preferred product, is required before one of the non-preferred agents will be approved unless one of the exceptions on the PA form is present. Toprol XL will be approved after a trial of an equivalent generic formulation when there is a diagnosis of cardiovascular complications, asthma, chronic bronchitis, COPD, or failure to achieve the desired outcomes on the generic formulation. |
| | BETA BLOCKER/DIURETIC COMBINATION DRUGS | | |
| | atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ nadolol/bendroflumethiazide propranolol/HCTZ | CORZIDE (nadolol/bendroflumethiazide) INDERIDE (propranolol/HCTZ) LOPRESSOR HCT (metoprolol/HCTZ) TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ) | |
| | BETA- AND ALPHA-BLOCKERS | | |
| | carvedilol labetalol | COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol) | |
| BLADDER RELAXANT PREPARATIONS | ENABLEX (darifenacin) oxybutynin oxybutynin ER SANCTURA (trospium) SANCTURA XR (trospium) VESICARE (solifenacin) OXYTROL (oxybutynin) | DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN (oxybutynin) DITROPAN XL (oxybutynin) | A trial of at least one of each of the chemically distinct preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|--|--|---|
| BONE RESORPTION SUPPRESSION AND RELATED AGENTS | BISPHOSPHONATES | | One of the preferred agents must be tried for at least one month before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| | alendronate FOSAMAX PLUS D (alendronate/vitamin D) | ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/calcium) BONIVA (ibandronate) DIDRONEL (etidronate) FOSAMAX (alendronate) | |
| | OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS | | Evista will be approved for postmenopausal women with osteoporosis or at high risk for invasive breast cancer. |
| | MIACALCIN (calcitonin) | EVISTA (raloxifene) FORTEO (teriparatide) FORTICAL (calcitonin) | |
| BPH AGENTS | 5-ALPHA-REDUCTASE (5AR) INHIBITORS | | A trial of at least two (2) chemically distinct preferred agents, including the generic formulation of a requested non-preferred agent, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| | AVODART (dutasteride) | PROSCAR (finasteride) finasteride | |
| | ALPHA BLOCKERS | | A trial of at least two (2) chemically distinct preferred agents, including the generic formulation of a requested non-preferred agent, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| | doxazosin FLOMAX (tamsulosin) terazosin UROXATRAL (alfuzosin) | CARDURA (doxazosin) CARDURA XL (doxazosin) HYTRIN (terazosin) | |
| BRONCHODILATORS, ANTICHOLINERGIC | ANTICHOLINERGIC | | The preferred agents in the class must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory. |
| | ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium) | ATROVENT Inhalation Solution (ipratropium) | |
| | ANTICHOLINERGIC-BETA AGONIST COMBINATIONS | | |
| | COMBIVENT (albuterol/ipratropium) | albuterol/ipratropium DUONEB (albuterol/ipratropium) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--------------------------------------|---|--|---|
| BRONCHODILATORS, BETA AGONIST | INHALATION SOLUTION | | <p>All of the preferred agents in a group must be tried before a non-preferred agent in that group will be authorized unless one of the exceptions on the PA form is present.</p> <p>Xopenex Inhalation Solution will be approved for 12 months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for concurrent diagnosis of heart disease.</p> <p>**No PA is required for ACCUNEB for children up to 5 years of age.</p> |
| | albuterol | ACCUNEB (albuterol)** BROVANA (arformoterol) ^{NR} metaproterenol PERFOROMIST (formoterol) ^{NR} PROVENTIL (albuterol) XOPENEX (levalbuterol) | |
| | INHALERS, LONG-ACTING | | |
| | FORADIL (formoterol) | SEREVENT (salmeterol) | |
| | INHALERS, SHORT-ACTING | | |
| | albuterol CFC MAXAIR (pirbuterol) PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol) | ALUPENT (metaproterenol) PROVENTIL (albuterol) | |
| ORAL | | | |
| albuterol terbutaline | BRETHINE (terbutaline) metaproterenol VOSPIRE ER (albuterol) | | |
| CALCIUM CHANNEL | LONG-ACTING | | The preferred agents must be tried before a non- |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|---|--|--|
| BLOCKERS (Oral) | amlodipine CARDIZEM LA (diltiazem) diltiazem DYNACIRC CR (isradipine) felodipine ER nifedipine ER nisoldipine verapamil ER VERELAN PM (verapamil) | ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD (diltiazem) CARDIZEM SR (diltiazem) COVERA-HS (verapamil) DILACOR XR (diltiazem) ISOPTIN SR (verapamil) NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine) TIAZAC (diltiazem) VERELAN (verapamil) | preferred agent will be approved. |
| | SHORT-ACTING | | |
| | diltiazem verapamil | ADALAT (nifedipine) CALAN (verapamil) CARDENE (nicardipine) CARDIZEM (diltiazem) DYNACIRC (isradipine) isradipine nicardipine nimodipine nifedipine NIMOTOP (nimodipine) PROCARDIA (nifedipine) | |
| CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral) | BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS | | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| | amoxicillin/clavulanate | | |
| | CEPHALOSPORINS | | |
| | cefaclor cefadroxil cefdinir cefpodoxime cefprozil cefuroxime cephalexin SPECTRACEF (cefditoren) | CECLOR (cefaclor) CEDAX (ceftibuten) CEFTIN (cefuroxime) CEFZIL (cefprozil) DURICEF (cefadroxil) KEFLEX (cephalexin) OMNICEF (cefdinir) PANIXINE (cephalexin) RANICLOR (cefaclor) SUPRAX (cefixime) VANTIN (cefpodoxime) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

CL – Requires Clinical PA

NR – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|--|---|---|
| CYTOKINE & CAM ANTAGONISTS^{CL} | ENBREL (etanercept) HUMIRA (adalimumab) KINERET (anakinra) RAPTIVA (efalizumab) | CIMZIA (certolizumab/pegol) ^{NR} | |
| ERYTHROPOIESIS STIMULATING PROTEINS^{CL} | ARANESP (darbepoetin) PROCRIT (rHuEPO) | EPOGEN (rHuEPO) | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| FLUOROQUINOLONES, ORAL | AVELOX (moxifloxacin) CIPRO (ciprofloxacin) Suspension ciprofloxacin ciprofloxacin ER LEVAQUIN (levofloxacin) | CIPRO (ciprofloxacin) Tablets CIPRO XR (ciprofloxacin) FACTIVE (gemifloxacin) FLOXIN (ofloxacin) NOROXIN (norfloxacin) ofloxacin PROQUIN XR (ciprofloxacin) | One of the preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| GENITAL WARTS AGENTS | ALDARA (imiquimod) | CONDYLOX (podofilox) podofilox VEREGEN (sinecatechins) | The preferred agent must be tried before a non-preferred agent will be authorized unless on of the exceptions on the PA form is present. |
| GLUCOCORTICOID, INHALED | GLUCOCORTICOIDS | | All of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present. Pulmicort Respules do not require a prior authorization for children through 8 years of age or for individuals unable to use an MDI. When children who have been stabilized on Pulmicort Respules reach age 9, prescriptions for the Pulmicort inhaler will be authorized for them. |
| | AEROBID (flunisolide) AEROBID-M (flunisolide) ASMANEX (mometasone) AZMACORT (triamcinolone) FLOVENT HFA (fluticasone) QVAR (beclomethasone) | ALVESCO ^{NR} (ciclesonide) PULMICORT (budesonide) | |
| | GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS | | |
| | ADVAIR (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) SYMBICORT (budesonide/formoterol) | | |
| GROWTH HORMONE^{CL} | GENOTROPIN (somatropin) NORDITROPIN (somatropin) NUTROPIN (somatropin) NUTROPIN AQ (somatropin) SAIZEN (somatropin) TEV-TROPIN (somatropin) | HUMATROPE (somatropin) INCRELEX (mecasermin) OMNITROPE (somatropin) SEROSTIM (somatropin) ZORBTIVE (somatropin) | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent for the duration of the existing PA. |
| HEPATITIS B TREATMENTS | EPIVIR HBV (lamivudine) HEPSERA (adefovir) TYZEKA (telbivudine) | BARACLUDE (entecavir) | One of the preferred agents must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| HEPATITIS C TREATMENTS^{CL} | PEGASYS (pegylated interferon) ribavirin | COPEGUS (ribavirin) INFERGEN (consensus interferon) PEG-INTRON (pegylated interferon) | Patients starting therapy in this class must try the preferred agent of a dosage form before a non-preferred agent of that dosage form will be |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|--|---|--|
| | | REBETOL (ribavirin) | authorized. |
| HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS | BYETTA (exenatide) JANUMET (sitagliptin/metformin) JANUVIA (sitagliptin) SYMLIN (amylin) | | Byetta and Symlin are both subject to the following step therapy edits: Byetta-Current history of therapy with a sulfonyleurea, thiazolidinedione (TZD), and/or metformin. No gaps of therapy greater than 30 days in the past 180 days. Symlin- History of insulin utilization in the past 90 days. No gaps in therapy of greater than 30 days. |
| HYPOGLYCEMICS, INSULINS | HUMALOG (insulin lispro) HUMALOG MIX (insulin lispro/lispro protamine) HUMULIN (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLIN (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine) | APIDRA (insulin glulisine) HUMALOG KWIKPEN (insulin lispro) | To receive Apidra, patients must meet the following criteria: 1. be 18 years or older; 2. be currently on a regimen including a longer-acting or basal insulin. 3. have had a trial of a similar preferred agent, Novolog or Humalog, with documentation that the desired results were not achieved. |
| HYPOGLYCEMICS, MEGLITINIDES | STARLIX (nateglinide) | PRANDIN (repaglinide) | The preferred agent must be tried before a non-preferred agent will be authorized, unless one of the exceptions on the PA form is present. |
| HYPOGLYCEMICS, TZDS | THIAZOLIDINEDIONES | | |
| | ACTOS (pioglitazone) AVANDIA (rosiglitazone) | | |
| | TZD COMBINATIONS | | |
| | ACTOPLUS MET (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin) AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride) | | |
| IMPETIGO AGENTS, TOPICAL | ALTABAX (retapamulin) mupirocin bacitracin gentamycin sulfate | BACTROBAN (mupirocin) CORTISPORIN (bacitracin/neomycin/polymyxin/HC) | A trial of one of at least one preferred agent, including the generic formulation of a requested non-preferred agent, must be tried for 10 days before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| INTRANASAL RHINITIS | ANTICHOLINERGICS | | All of the preferred agents, in corresponding |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|-------------------------------|---|--|--|
| AGENTS | | ATROVENT(ipratropium) ipratropium ANTIHISTAMINES ASTELIN (azelastine) CORTICOSTEROIDS fluticasone propionate NASACORT AQ (triamcinolone) NASONEX (mometasone) VERAMYST (fluticasone furoate) | categories, must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| LEUKOTRIENE MODIFIERS | ACCOLATE (zafirlukast) SINGULAIR (montelukast) | ZYFLO (zileuton) | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| LIPOTROPICS, OTHER | BILE ACID SEQUESTRANTS | | One of the preferred agents must be tried before a |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|---|---|--|
| (non-statins) | cholestyramine colestipol | COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevelam) | non-preferred agent in the corresponding category will be authorized. Zetia, as monotherapy, will only be approved for patients who cannot take statins or other preferred agents. Zetia and Welchol will be approved for add-on therapy only after an insufficient response to the maximum tolerable dose of a statin after 12 weeks of therapy. |
| | CHOLESTEROL ABSORPTION INHIBITORS | | |
| | | ZETIA (ezetimibe) | |
| | FATTY ACIDS | | |
| | | LOVAZA (omega-3-acid ethyl esters) | |
| | FIBRIC ACID DERIVATIVES | | |
| | fenofibrate gemfibrozil TRICOR (fenofibrate) | ANTARA (fenofibrate) fenofibrate, micronized LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate) | |
| | NIACIN | | |
| niacin NIASPAN (niacin) | NIACELS (niacin) NIADELAY (niacin) SLO-NIACIN (niacin) | | |
| LIPOTROPICS, STATINS | STATINS | | One of the preferred statins, including the generic formulation of a requested non-preferred agent, must be tried for 12 weeks before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present Vytorin will be approved only after an insufficient response to the maximum tolerable dose of Lipitor (atorvastatin) or Crestor (rosuvastatin) after 12 weeks, unless one of the exceptions on the PA form is present. Members on Vytorin 10/80 will be grandfathered on that therapy. Members on all other strengths of Vytorin will be grandfathered until 6/30/08 on that therapy, but their prescriptions will require prior authorization after that period. (See letter to providers.) |
| | CRESTOR (rosuvastatin) LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin) lovastatin pravastatin simvastatin | ALTOPREV (lovastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin) | |
| | STATIN COMBINATIONS | | |
| | ADVICOR (lovastatin/niacin) CADUET (atorvastatin/amlodipine) SIMCOR (simvastatin/niacin ER) | VYTORIN (simvastatin/ ezetimibe) | |
| MACROLIDES/KETOLIDES (Oral) | KETOLIDES | | Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past 28 days. |
| | | KETEK (telithromycin) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|---|--|---|
| | MACROLIDES | | |
| | azithromycin clarithromycin erythromycin | BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) clarithromycin ER E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin) | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |
| MULTIPLE SCLEROSIS AGENTS ^{CL} | AVONEX (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE (glatiramer) REBIF (interferon beta-1a) | TYSABRI (natalizumab) | A trial of a preferred agent will be required before a trial of a non-preferred agent will be approved. Tysabri will only be approved for members who meet the conditions and are enrolled the TOUCH Prescribing Program. |
| NSAIDS | NONSELECTIVE | | |
| | diclofenac etodolac fenoprofen flurbiprofen ibuprofen (Rx and OTC) INDOCIN (indomethacin) (suspension only) indomethacin ketorolac naproxen (Rx only) oxaprozin piroxicam sulindac | ADVIL (ibuprofen) ANAPROX (naproxen) ANSAID (flurbiprofen) CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) FELDENE (piroxicam) FLECTOR PATCH (diclofenac) ^{NR} INDOCIN (indomethacin) ketoprofen LODINE (etodolac) meclofenamate mefenamic acid MOTRIN (ibuprofen) nabumetone NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) NUPRIN (ibuprofen) ORUDIS (ketoprofen) PONSTEL (meclofenamate) | The preferred agents must be tried before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--|--|---|---|
| | | tolmetin VOLTAREN (diclofenac) VOLTAREN GEL (diclofenac) ^{NR} | |
| | NSAID/GI PROTECTANT COMBINATIONS | | |
| | | ARTHROTEC (diclofenac/misoprostol) PREVACID/NAPRAPAC (naproxen/lansoprazole) | |
| | COX-II SELECTIVE^{CL} | | |
| | | CELEBREX (celecoxib) meloxicam MOBIC (meloxicam) | COX-II selective NSAIDs will be approved for patients with a GI Risk Score of ≥ 13 . |
| OPHTHALMIC ANTIBIOTICS | ciprofloxacin ofloxacin VIGAMOX (moxifloxacin) | AZASITE (azithromycin) CILOXAN (ciprofloxacin) OCUFLOX (ofloxacin) QUIXIN (levofloxacin) ZYMAR (gatifloxacin) | All of the preferred agents must be tried before non-preferred agents will be authorized unless one of the exceptions on the PA form is present. |
| OPHTHALMIC NSAIDS | ACULAR LS (ketorolac) ACULAR PF (ketorolac) flurbiprofen NEVANAC (nepafenac) XIBROM (bromfenac) | diclofenac DUREZOL (difluprednate) ^{NR} | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. |
| OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS | ACULAR (ketorolac) ALAWAY (ketotifen) ALREX (loteprednol) cromolyn ELESTAT (epinastine) OPTIVAR (azelastine) PATADAY (olopatadine) PATANOL (olopatadine) ZADITOR OTC (ketotifen) | ALAMAST (pemirolast) ALOCRIL (nedocromil) ALOMIDE (lodoxamide) CROLOM (cromolyn) EMADINE (emedastine) ketotifen OPTICROM (cromolyn) | Two of the preferred agents must be tried before non-preferred agents will be authorized, unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|--|--|--|
| OPHTHALMICS, GLAUCOMA AGENTS | COMBINATION AGENTS | | Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents. |
| | COSOPT (dorzolamide/timolol) | COMBIGAN (brimonidine/timolol) | |
| | BETA BLOCKERS | | |
| | Betaxolol BETIMOL (timolol) BETOPTIC S (betaxolol) carteolol ISTALOL (timolol) levobunolol metipranolol timolol | BETAGAN (levobunolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol) | |
| | CARBONIC ANHYDRASE INHIBITORS | | |
| | AZOPT (brinzolamide) TRUSOPT (dorzolamide) | | |
| | PARASYMPATHOMIMETICS | | |
| | CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine | ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine) | |
| | PROSTAGLANDIN ANALOGS | | |
| | LUMIGAN (bimatoprost) TRAVATAN (travoprost) TRAVATAN-Z (travoprost) | XALATAN (latanoprost) | |
| SYMPATHOMIMETICS | | | |
| ALPHAGAN P (brimonidine) brimonidine dipivefrin | ALPHAGAN (brimonidine) PROPINE (dipivefrin) | | |
| OTIC FLUOROQUINOLONES | CIPRODEX (ciprofloxacin/dexamethasone) ofloxacin | CIPRO HC (ciprofloxacin/hydrocortisone) FLOXIN (ofloxacin) | Each of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|---|--|---|---|
| PANCREATIC ENZYMES | CREON PANCREARB ULTRASE ULTRASE MT VIOKASE | KUZYME LIPRAM PALCAPS PANCREASE PANGESTYME PANOKASE PLARETASE | A trial of at least 3 preferred agents, for at least 30 days each, is required before a non-preferred agent will be authorized unless one of the exceptions on the PA form is present. Non-preferred agents will be approved for members with cystic fibrosis. In all cases except cystic fibrosis, objective evidence of pancreatic insufficiency (fat malabsorption, etc.) must be documented. |
| PARATHYROID AGENTS | ergocalciferol calcitriol HECTOROL (doxercalciferol) ZEMPLAR (paricalcitol) | DRISDOL (ergocalciferol) ROCALTROL (calcitriol) SENSIPAR (cinacalcet) | A trial of a non-preferred agent will be required, for at least 30 days, before a non-preferred agent will be approved. Prescriptions for Sensipar will be grandfathered. |
| PEDICULICIDES/ SCABICIDES, TOPICAL | EURAX (crotamiton) OVIDE (malathion) permethrins (Rx and OTC) pyrethrins-piperonyl butoxide | lindane | A trial of all three pediculicides (Ovide, permethrins, and pyrethrins-piperonyl butoxide) is required before lindane will be approved unless one of the exceptions on the PA form is present. |
| PHOSPHATE BINDERS | FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENAGEL (sevelamer) | REVELA (sevelamer carbonate) ^{NR} | A trial of at least two preferred agents will be required unless one of the exceptions on the PA form is present. |
| PLATELET AGGREGATION INHIBITORS | AGGRENOX (dipyridamole/ASA) cilostazol PLAVIX (clopidogrel) | dipyridamole PERSANTINE (dipyridamole) PLETAL (cilostazol) TICLID (ticlopidine) ticlopidine | All of the preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. |
| PROTON PUMP INHIBITORS | NEXIUM (esomeprazole) PREVACID Capsules (lansoprazole) | ACIPHEX (rabeprazole) NEXIUM PACKETS (esomeprazole) omeprazole pantoprazole PREVACID Solu-Tabs (lansoprazole) PREVACID Suspension (lansoprazole) PRILOSEC (omeprazole) PROTONIX (pantoprazole) ZEGERID (omeprazole/sodium bicarbonate) | The preferred agents must be tried before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Prior authorization is not required for Prevacid Solu-Tabs for patients ≤8 years of age. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|-------------------------------|--|--|--|
| SEDATIVE HYPNOTICS | BENZODIAZEPINES | | The preferred agent must be tried for 14 days before a nonpreferred agent will be authorized unless one of the exceptions on the PA form is present. |
| | temazepam | DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) PROSOM (estazolam) RESTORIL (temazepam) triazolam | |
| | OTHERS | | |
| | zolpidem | AMBIEN (zolpidem) AMBIEN CR (zolpidem) AQUA CHLORAL (chloral hydrate) chloral hydrate LUNESTA (eszopiclone) ROZEREM (ramelteon) SOMNOTE (chloral hydrate) SONATA (zaleplon) zaleplon ^{NR} | |
| STIMULANTS AND RELATED AGENTS | AMPHETAMINES | | Except for Strattera, PA is required for adults >18 years. One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried before a non-preferred agent will be authorized. Amphetamines will be authorized for the treatment of depression only after documented failure of multiple antidepressants. Provigil will only be approved for patients >16 years of age with a diagnosis of narcolepsy. Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for 30 days or less for tapering purposes. Only two doses of each strength, or two concurrent doses of any strength, and a maximum of one dose of a 60 mg capsule, will be approved in a 34-day period. |
| | ADDERALL XR (amphetamine salt combination) amphetamine salt combination dextroamphetamine VYVANSE (lisdexamphetamine) | ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) DEXEDRINE (dextroamphetamine) DEXTROSTAT (dextroamphetamine) | |
| | NON-AMPHETAMINE | | |
| | CONCERTA (methylphenidate) DAYTRANA (methylphenidate) FOCALIN (dexmethylphenidate) FOCALIN XR (dexmethylphenidate) METADATE CD (methylphenidate) methylphenidate methylphenidate ER STRATTERA (atomoxetine) | dexmethylphenidate METADATE ER (methylphenidate) pemoline PROVIGIL (modafinil) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN-SR (methylphenidate) | |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee

**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

Effective 11/3/08
Version 2008.8

| THERAPEUTIC DRUG CLASS | PREFERRED AGENTS | NON-PREFERRED AGENTS | PA CRITERIA |
|--------------------------------------|--|---|---|
| ULCERATIVE COLITIS AGENTS | ORAL | | The preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one of the exceptions on the PA form is present. |
| | ASACOL (mesalamine) COLAZAL (balsalazide) DIPENTUM (olsalazine) PENTASA (mesalamine) sulfasalazine | AZULFIDINE (sulfasalazine) LIALDA (mesalamine) | |
| | RECTAL | | |
| | CANASA (mesalamine) mesalamine | ROWASA (mesalamine) | |
| MISC BRAND/GENERIC | SANDOSTATIN (octreotide) | octreotide | The preferred agent must be tried before the non-preferred agent will be authorized unless one of the exceptions on the PA form is present. |

Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC are not covered unless specified.

^{CL} – Requires Clinical PA

^{NR} – New drug has not been reviewed by P & T Committee